0001209191-21-011065.txt : 20210216
0001209191-21-011065.hdr.sgml : 20210216
20210216202612
ACCESSION NUMBER: 0001209191-21-011065
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210214
FILED AS OF DATE: 20210216
DATE AS OF CHANGE: 20210216
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GRIFFIN MICHELLE RENEE
CENTRAL INDEX KEY: 0001229765
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38957
FILM NUMBER: 21642133
MAIL ADDRESS:
STREET 1: 19723 NE 65TH LANE
CITY: KIRKLAND
STATE: WA
ZIP: 98033
FORMER NAME:
FORMER CONFORMED NAME: BURRIS MICHELLE
DATE OF NAME CHANGE: 20030429
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Adaptive Biotechnologies Corp
CENTRAL INDEX KEY: 0001478320
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 270907024
STATE OF INCORPORATION: WA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1551 EASTLAKE AVENUE EAST SUITE 200
CITY: SEATTLE
STATE: WA
ZIP: 98102
BUSINESS PHONE: 206-659-0067
MAIL ADDRESS:
STREET 1: 1551 EASTLAKE AVENUE EAST SUITE 200
CITY: SEATTLE
STATE: WA
ZIP: 98102
FORMER COMPANY:
FORMER CONFORMED NAME: Adaptive TCR Corp
DATE OF NAME CHANGE: 20091209
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-02-14
0
0001478320
Adaptive Biotechnologies Corp
ADPT
0001229765
GRIFFIN MICHELLE RENEE
C/O ADAPTIVE BIOTECHNOLOGIES CORP.
SUITE 200
SEATTLE
WA
98102
1
0
0
0
Common Stock
2021-02-14
4
A
0
1504
0.00
A
1504
D
Common Stock
2021-02-16
4
M
0
6000
7.80
A
7504
D
Common Stock
2021-02-16
4
S
0
6000
65.08
D
1504
D
Stock Option (Right to Buy)
66.50
2021-02-14
4
A
0
3759
0.00
A
2031-02-14
Common Stock
3759
3759
D
Stock Option (Right to Buy)
7.80
2021-02-16
4
M
0
6000
0.00
D
2029-04-23
Common Stock
6000
89000
D
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020.
The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $64.49 to 65.45, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
The option will vest in equal monthly installments over one year, subject to continued service as a director through such vesting date.
The options vested with respect to 1/4 of such shares on March 28, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
/s/ Michelle Griffin by Eric Billings, attorney-in-fact
2021-02-17